Clinical significance of the diagnosis of sarcopenic obesity in people with type 2 diabetes.

Fushi Higashine, Shota Oda, Rina Hosoda
Purpose:

To examine the clinical significance of uniform diagnostic criteria for sarcopenia obesity in Japan.


Methods:

A retrospective cross-sectional study was conducted percent body fat (PBF) and Limb skeletal muscle mass (LSM) were assessed using InBody 720TM. The diagnostic items for sarcopenic obesity were hand grip (Males(M):28 kg; Females(F):18 kg), LSM corrected for BMI (M:0.789kg/BMI; F:0.512kg/BMI), and body fat percentage (M:≥20% ; F:≥30%) based on previous reports. Chi-square tests were used to examine the association between obesity sarcopenia. Logistic regression models were used to explore the association between risk of occurrence of adverse and Sarcopenic Obesity. Adverse events were defined as mortality, hospitalization, falls, fracture, diabetic macroangiopathy within 5 years.


Results:

A total of 37 people with T2D [M:18 and F:19, 20 sarcopenic obesity and 17 non- sarcopenic obesity] were included in this study. The age was 68.9±10.7y. LSM was 0.63±0.12kg/BMI

There was a significant relationship between sarcopenic obesity and adverse events.

The significantly associated risk factor for adverse events at 5 years in people with T2D was sarcopenic obesity (OR 1.036 [95% CI: 1.016-1.057]), but not age or gender.


Conclusion(s):

Sarcopenic obesity is associated with an increased risk of adverse outcomes physical disability, and mortality and diabetic macroangiopathy.

Implications:

A diagnosis of sarcopenia obesity was suggested to be a possible predictor of adverse events at 5 years.

Funding acknowledgements:
The work was unfunded
Keywords:
sarcopenia
obesity
diabetes
Primary topic:
Sustainable health
Second topic:
Musculoskeletal
Third topic:
Other
Did this work require ethics approval?:
Yes
Name the institution and ethics committee that approved your work:
The Ethics Committee of the Kochi University School of Medicine. (Approval number 2022-78)
Provide the ethics approval number:
2022－78
Has any of this material been/due to be published or presented at another national or international conference prior to the World Physiotherapy Congress 2025?:
No

Back to the listing